{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-001139","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.975439+00:00","generated_at":"2026-06-07T04:01:56.065376+00:00","sec_items":["1.01","3.02","8.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rhythm Pharmaceuticals licenses LB54640 from LG Chem for $60M upfront plus $40M deferred","bullets":["License deal: $40M cash + $20M stock upfront; additional $40M cash due 18 months after effective date.","Up to $205M in regulatory and sales milestones; low-to-mid single-digit royalties on MC4R portfolio starting 2029.","Rhythm assumes sponsorship of two Phase 2 studies: SIGNAL (hypothalamic obesity, ~28 patients) and ROUTE (POMC/LEPR deficiency, 5 patients).","Cash guidance updated: existing cash sufficient into H2 2025, including $80M fixed payments to LG Chem."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-001139","json":"https://secwatch.observer/filing/0001104659-24-001139.json","markdown":"https://secwatch.observer/filing/0001104659-24-001139.md","text":"https://secwatch.observer/filing/0001104659-24-001139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465924001139/0001104659-24-001139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465924001139/tm2332524d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:01:56.065376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59d3abef5af6f94bf3cde98843632139e3cbc0f4","claim":"RHYTHM PHARMACEUTICALS, INC. entered into Share Issuance Agreement with LG Chem, Ltd. (effective 2024-01-04).","evidence_excerpt":"The Share Issuance Agreement contains customary representations and warranties by the Company and LGC, and the issuance of the Shares is subject to certain customary closing conditions.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465924001139/0001104659-24-001139-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"LG Chem, Ltd."},{"label":"Effective","value":"2024-01-04"}],"fact_type":"material_agreement"},{"claim_id":"a4a6b9b2976f975a15b0467b31b94587ac6d212f","claim":"RHYTHM PHARMACEUTICALS, INC. entered into License Agreement with LG Chem, Ltd. valued at $40 million in cash and issue shares of its common stock, par value of $0.001, with an aggregate val (effective 2024-01-04).","evidence_excerpt":"Under the terms of the License Agreement, the Company will obtain worldwide rights to exploit LGC’s proprietary compound LB54640 and will assume sponsorship of two ongoing LGC Phase 2 studies designed to evaluate safety, tolerability, pharmacokinetics and weight loss efficacy of LB54640.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465924001139/0001104659-24-001139-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"LG Chem, Ltd."},{"label":"Value","value":"$40 million in cash and issue shares of its common stock, par value of $0.001, with an aggregate val"},{"label":"Effective","value":"2024-01-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}